2022 Fiscal Year Final Research Report
The significance of lysophosphatidylserine in the field of thrombosis and hemostasis and clinical laboratory applications
Project/Area Number |
19K16971
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 52010:General internal medicine-related
|
Research Institution | The University of Tokyo |
Principal Investigator |
|
Project Period (FY) |
2019-04-01 – 2023-03-31
|
Keywords | 血小板 / リゾホスファチジルセリン / 臨床検査医学 |
Outline of Final Research Achievements |
Lysophosphatidylserine (LysoPS), one of lysophospholipid, has attracted much attention as a novel lysophospholipid mediator with potent immunosuppressive activity against lymphocytes and macrophages. LysoPS is elevated in the plasma of patients with acute coronary syndromes, in which platelet activation is an important factor, and LysoPS receptors have been shown to be present on platelets. The aim of this study was to elucidate the role of LysoPS in the area of thrombosis and hemostasis, and to further apply the results to clinical laboratory medicine. Platelets are a heterogeneous cell population, and we used a measurement system that combines flow cytometry and FISH as a method to evaluate each platelet individually.
|
Free Research Field |
臨床検査医学、血栓止血学
|
Academic Significance and Societal Importance of the Research Achievements |
リゾリン脂質は親水基である残基と疎水性部位を有するリン脂質の総称であり,申請者の所属する研究グループを含め,ヒト疾患との関連が盛んに研究されている.代表的なリゾリン脂質は,リゾホスファチジン酸(LPA)とスフィンゴシン1リン酸(S1P)であるが,申請者はLPA,S1Pに次ぐリゾリン脂質メディエーターとして,リゾホスファチジルセリン(LysoPS)に注目した.LysoPSは,2012年に3種の特異的G蛋白共役型受容体(GPR34, P2Y10, GPR174)が同定され,その作用は免疫学を中心に明らかになってきたが,血栓止血領域におけるLysoPSの意義は明らかになっていない.
|